Obesity, Overweight
Conditions
Keywords
Obesity Disease, Metabolic Disorders, Body Weight Loss
Brief summary
The main purpose of this study is to learn about the side effects of LY3841136 alone and in combination with tirzepatide, when given to Japanese participants with obese or overweight. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. Part A of the study will last about 28 weeks and may include up to 17 visits. Part B of the study will last about 40 weeks and may include up to 29 visits.
Interventions
DRUGLY3841136
Administered SC
DRUGLY3841136-Placebo
Administered SC
DRUGTirzepatide
Administered SC
Administered SC
Sponsors
Eli Lilly and Company
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Male or female participants who agree to contraception requirements * Have a body mass index (BMI) within the range of 27 to 40 kg/m², inclusive * Have had a stable weight for the 3 months
Exclusion criteria
* Have a history of significant atopy (severe allergic manifestations), multiple or severe drug allergies, or severe posttreatment hypersensitivity reactions * Have a history or presence of psychiatric disorders, including a history of major depressive disorder or severe psychiatric disorders such as schizophrenia, bipolar disorder within the last 3 years * Have been diagnosed with Type 1 or Type 2 Diabetes Mellitus * Have a history of chronic medical conditions involving the heart, liver, or kidneys * Have a history of any malignancy within the past 5 years * Have a history or presence of a GI disorder * Have had within the last 6 months, or plan to have during the study, a device-based or surgical treatment use for obesity * Have been treated, or plan to be treated, with prescription medications or other non-approved drugs intended to promote weight loss, within 3 months prior to screening * For participants in Part B, have previously received tirzepatide within 6 months prior to screening * For participants in Part B, have a personal or family history of medullary thyroid carcinoma, or have multiple endocrine neoplasia syndrome type 2
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Part A: Number of Participants with One or More Serious Adverse Events (SAE) Considered by the Investigator to be Related to Study Drug Administration at Week 22 | Baseline through Week 22 | A summary of treatment emergent adverse events (TEAEs), SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module |
| Part B: Number of Participants with One or More Serious Adverse Events (SAE) Considered by the Investigator to be Related to Study Drug Administration at Week 34 | Baseline through Week 34 | A summary of treatment emergent adverse events (TEAEs), SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Part A Pharmacodynamics (PD): Change From Baseline in Body Weight at Week 12 | Baseline through Week 12 | PD: Change from baseline in body weight |
| Part B PK: AUC of LY3841136 in Combination with Tirzepatide | Predose through Week 34 | PK: AUC of LY3841136 in combination with tirzepatide |
| Part A Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3841136 | Predose through Week 22 | PK: AUC of LY3841136 alone |
| Part B PD: Change From Baseline in Body Weight at Week 24 | Baseline through Week 24 | PD: Change from baseline in body weight |
| Part B PK: Cmax of LY3841136 in Combination with Tirzepatide | Predose through Week 34 | PK: Cmax of LY3841136 in combination with tirzepatide |
| Part A PK: Maximum Observed Concentration (Cmax) of LY3841136 | Predose through Week 22 | PK: Cmax of LY3841136 alone |
Countries
Japan
Outcome results
None listed